Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Relapse Remitting Multiple Sclerosis Clear all
Completed Phase 3 Interventional Results available

Vitamin D Supplementation in Multiple Sclerosis

NCT01490502
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Vitamin D3
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
16
States / cities
Carmichael, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 16, 2026, 9:20 PM EDT
Completed No phase listed Observational

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

NCT06526000
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 16, 2026, 9:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

NCT04448977
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrevus
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 9:20 PM EDT
Recruiting Not applicable Interventional

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

NCT06919900
View directory record Official record
Conditions
Multiple Sclerosis (Relapsing Remitting)
Interventions
Perturbation Training, Treadmill Walking
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
45 Years to 89 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 16, 2026, 9:20 PM EDT
Terminated Phase 2 Interventional Results available

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

NCT04767698
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 16, 2026, 9:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

NCT00914758
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington Neuropsychology Research Group
Other
Eligibility
25 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2009 · Synced Oct 16, 2026, 9:20 PM EDT
Completed No phase listed Observational

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

NCT00232193
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
Providence Multiple Sclerosis Center
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
HB-adMSCs, Placebo
Biological · Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 16, 2026, 9:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

An Examination of Cognitive Fatigue Using Functional Neuroimaging

NCT04885894
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Zeposia
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Copaxone®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Phase 4 Interventional

A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

NCT00315367
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Donepezil HCI (drug)
Drug
Lead sponsor
Neurognostics
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00355134
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
100
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

NCT00176592
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Betaseron, Copaxone
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

NCT02040298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 16, 2026, 9:20 PM EDT
Recruiting Not applicable Interventional

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

NCT06864936
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab, Other disease modifying therapies
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 9:20 PM EDT
Terminated No phase listed Observational

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

NCT00398528
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Glatiramer acetate, (Copaxone®), IFN-β-1a, (Avonex®)
Drug
Lead sponsor
Neurognostics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Los Angeles, California • Seattle, Washington • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 16, 2026, 9:20 PM EDT
Completed No phase listed Observational

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

NCT00463710
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex® monotherapy (6.0 MIU administered i.m. each week)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 16, 2026, 9:20 PM EDT
Completed No phase listed Observational

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

NCT01485003
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
44
States / cities
Homewood, Alabama • Sun City, Arizona • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 16, 2026, 9:20 PM EDT
Completed No phase listed Observational Results available

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

NCT03562975
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 16, 2026, 9:20 PM EDT
Withdrawn Not applicable Interventional

Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

NCT05482542
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab
Other · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 58 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 16, 2026, 9:20 PM EDT
Terminated No phase listed Observational

Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

NCT05978531
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Monomethyl Fumarate
Drug
Lead sponsor
Banner Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 16, 2026, 9:20 PM EDT
Terminated Phase 1Phase 2 Interventional

Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor

NCT00095329
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
sirolimus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 58 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 16, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

NCT00645749
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Helminth ova
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 16, 2026, 9:20 PM EDT